About Glycomine
Glycomine is a Healthcare company based in San Francisco (United States) founded in 2015. Replacement therapies for rare genetic diseases are developed and provided. Glycomine has raised $195 million across 4 funding rounds from investors including abrdn, Asahi Kasei and Abingworth. Its focus areas include Life Sciences, Rare Diseases, Drugs and Metabolic Disorders. Its competitors include Alnylam, Ultragenyx and Gemini Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Glycomine was founded in 2015 and is headquartered in San Francisco, United States. Focus is placed on the biotechnology sector, where replacement therapies for rare genetic diseases are developed. Nanocarriers are being created to deliver proteins into affected cells and tissues. The drug pipeline features M1P substrate replacement therapy for Congenital Disorder of Glycosylation (CDG-Ia) and rhNgly1 enzyme replacement therapy for NGLY1 deficiency.
- Headquarters San Francisco, United States
- SectorsHealthcare
- Email••••••••
- Website glycomine.com
- Social LinkedIn X
- Total Equity Funding$195M (USD)
in 4 rounds
- Latest Funding Round$115M (USD), Series C
Apr 2025
- Investorsabrdn
& 14 more
Funding Insights of Glycomine
Glycomine has successfully raised a total of $195M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $115 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $195M
- Total Rounds 4
- Last Round Series C — $115M
- First Round $12M
(Nov 2016)
- Investors Count 15
All 4 funding rounds of Glycomine with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2025 | $115M | Series C | – | CTI Life Sciences Fund, abrdn | |
| Jun 2021 | $35M | Series B | – | Abingworth, Sanofi Ventures | |
| Aug 2019 | $33M | Series B | – | Novo Holdings | |
| Nov 2016 | $12M | Series A | – | Sanderling Ventures |
15 investors in total: 15 institutional.
Investors in Glycomine
Glycomine has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include abrdn, Asahi Kasei and Abingworth.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are made in life sciences companies. | ctisciences.com | Montreal, Canada | ||
Multiple sectors are invested in by abrdn's private equity fund. | 1825 | abrdn.com | Edinburgh, United Kingdom | |
Early and mid-stage life science focused VC firm investing in the US and Europe | adventls.com | London, United Kingdom | ||
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Life-Sciences focused Early stage Corporate VC Firm investing in the US | sanofiventures.com | Paris, France | ||
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
| rivervest.com | ||||
Biomedical investment financing and active management services. | sanderling.com | |||
Chiesi Ventures is focused on venture capital for rare diseases. | chiesiventures.com | Boston, United States | ||
Remiges Ventures is engaged in biotech venture capital investments. | remigesventures.com | Seattle, United States |
Investor details for Glycomine
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Glycomine
20 people are tracked at Glycomine (9 in leadership, 9 in board & advisors, 2 in team).
| Name | Role | Group |
|---|---|---|
Rose Marino | Chief Medical Officer | Leadership |
Steven Axon | Director & CEO | Leadership |
Peter McWilliams | Chief Business Officer | Leadership |
Geoffrey Hird | Chief Technology Officer | Leadership |
Hicham Alaoui | Chief Scientific Officer | Leadership |
Teppei Shirakura | Director of Chemistry | Leadership |
Emily Tess | Chief of Staff, Director of Corporate Development & Strategy | Leadership |
Kevin Herlihy | Sr. Director Manufacturing Science And Technology | Leadership |
Drew Folk | Sr. Director Of Product Development | Leadership |
Tim Mills | Board Member | Board & advisors |
Hudson H. Freeze | Advisor | Board & advisors |
Niall O’Donnell | Director | Board & advisors |
Gregory Enns | Advisor | Board & advisors |
Chris Starr | Chairperson | Board & advisors |
Jim Trenkle | Director | Board & advisors |
Ken Harrison | Director | Board & advisors |
Jackie Grant | Director | Board & advisors |
Jason Hafler | Director | Board & advisors |
Lakshmi Krishnamoorthy | Senior Scientitst | Team |
Yousef Zoumot | Senior IT Engineer | Team |
Complete people profiles for Glycomine
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Glycomine
3 dated milestones of Glycomine across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Glycomine is founded.
- Funding First funding round of $12.0M.
- Funding Latest funding round, Series C, of $115.0M.
Competitors of Glycomine
Glycomine has 3 listed competitors in our database, 3 of them funded. They include Alnylam, Ultragenyx and Gemini Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| geminitherapeutics.com | 2015 | Cambridge, United States | $44.5M | 45 | Developer of precision therapeutics for dry AMD and rare genetic diseases |
Detailed competitors of Glycomine
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Glycomine
The website of Glycomine (glycomine.com) receives about 2.3K visits a month.
- Monthly visits2.3K
▼ 21.4% vs previous month
Websites whose visitors overlap most with Glycomine. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| appliedtherapeutics.com | 100% | 6.2K | #1,771,734 | View details |
Top companies in Rare Diseases
3 companies that operate in the same segment as Glycomine (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Glycomine
Complete news archive for Glycomine
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Glycomine
Glycomine was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Glycomine is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Glycomine is a funded company, having raised a total of $195M across 4 funding rounds to date. The company's 1st funding round was a Series A of $12M, raised on Nov 2016.
Glycomine was founded in 2015 and is headquartered in San Francisco, United States. Focus is placed on the biotechnology sector, where replacement therapies for rare genetic diseases are developed. Nanocarriers are being created to deliver proteins into affected cells and tissues. The drug pipeline features M1P substrate replacement therapy for Congenital Disorder of Glycosylation (CDG-Ia) and rhNgly1 enzyme replacement therapy for NGLY1 deficiency.
Glycomine's top competitors include Alnylam, Ultragenyx and Gemini Therapeutics.
Glycomine has 15 investors. Key investors include abrdn, Asahi Kasei, Abingworth, CTI Life Sciences, and Advent Life Sciences.